Matrix detachment and proteasomal inhibitors diminish Sulf-2 expression in breast cancer cell lines and mouse xenografts

Clinical and Experimental Metastasis

Volumn 30, Issue 4, 2013, Pages 407-415

  Khurana, Ashwani ^a   Jung Beom, Deok ^b   He, Xiaoping ^a   Kim, Sung Hoon ^b   Busby, Robert C ^a   Lorenzon, Laura ^c   Villa, Massimo ^d   Baldi, Alfonso ^e   Molina, Julian ^a   Goetz, Matthew P ^a   Shridhar, Viji ^a  

^a MAYO CLINIC   (United States)

^b Kyung Hee University   (South Korea)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^e UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Breast cancer; Growth factor; Sulfatase 2

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; LACTACYSTIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SULFATASE; SULFATASE 2; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER SIZE; CELL DEATH; CELL STRAIN MCF 7; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTRADUCTAL CARCINOMA; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CELL PROLIFERATION; EXTRACELLULAR MATRIX; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; NEOPLASM GRADING; PROTEASOME INHIBITORS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SULFOTRANSFERASES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876469098     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-012-9546-5     Document Type: Article

References (27)

1. Bernfield M, Gotte M, Park PW et al (1999) Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68:729-777
2. Chua CC, Rahimi N, Forsten-Williams K et al (2004) Heparan sulfate proteoglycans function as receptors for fibroblast growth factor-2 activation of extracellular signal-regulated kinases 1 and 2. Circ Res 94(3):316-323
3. Morimoto-Tomita M, Uchimura K, Werb Z et al (2002) Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans. J Biol Chem 277(51):49175-49185
4. Morimoto-Tomita M, Uchimura K, Bistrup A et al (2005) Sulf-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer. Neoplasia 7(11):1001-1010
5. Peterson SM, Iskenderian A, Cook L et al (2010) Human Sulfatase 2 inhibits in vivo tumor growth of MDA-MB-231 human breast cancer xenografts. BMC cancer 10:427
6. Khurana A, Liu P, Mellone P et al (2011) HSulf-1 modulates FGF2- and hypoxia-mediated migration and invasion of breast cancer cells. Cancer Res 71(6):2152-2161
7. Sabe H (2011) Cancer early dissemination: cancerous epithelial- mesenchymal transdifferentiation and transforming growth factor beta signalling. J Biochem 149(6):633-639
8. Tait LR, Pauley RJ, Santner SJ et al (2007) Dynamic stromal-epithelial interactions during progression of MCF10DCIS.com xenografts. Int J Cancer 120(10):2127-2134
9. Miller FR, Santner SJ, Tait L et al (2000) MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst 92(14):1185-1186
10. Nannuru KC, Futakuchi M, Varney ML et al (2010) Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-{beta} signaling at the tumor-bone interface. Cancer Res. doi: 10.1158/0008-5472
11. Stetler-Stevenson WG (2001) The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesis. Surg Oncol Clin N Am 10(2):383-392
12. Lai J, Chien J, Staub J et al (2003) Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem 278(25):23107-23117
13. Narita K, Staub J, Chien J et al (2006) HSulf-1 inhibits angiogenesis and tumorigenesis in vivo. Cancer Res 66(12):6025-6032
14. Khurana A, Nakayama K, Williams S et al (2006) Regulation of the ring finger E3 ligase Siah2 by p38 MAPK. J Biol Chem 281(46):35316-35326
15. Khurana A, Tun HW, Marlow L et al (2011) Hypoxia negatively regulates heparan sulfatase 2 expression in renal cancer cell lines. Mol carcinog 51(7):565-575
16. Khurana A, McKean H, Kim H et al (2012) Silencing of HSulf-2 expression in MCF10DCIS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo. Breast Cancer Res 14(2):R43
17. Lai JP, Sandhu DS, Yu C et al (2008) Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 47(4):1211-1222
18. Shekhar MP, Tait L, Pauley RJ et al (2008) Comedo-ductal carcinoma in situ: a paradoxical role for programmed cell death. Cancer Biol Ther 7(11):1774-1782
19. Debnath J, Mills KR, Collins NL et al (2002) The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 111(1):29-40
20. Reginato MJ, Mills KR, Paulus JK et al (2003) Integrins and EGFR coordinately regulate the pro-apoptotic protein bim to prevent anoikis. Nat Cell Biol 5(8):733-740
21. Haenssen KK, Caldwell SA, Shahriari KS et al (2010) ErbB2 requires integrin alpha5 for anoikis resistance via Src regulation of receptor activity in human mammary epithelial cells. J Cell Sci 123(Pt 8):1373-1382
22. Powers GL, Ellison-Zelski SJ, Casa AJ et al (2010) Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer. Oncogene 29(10):1509-1518
23. Marx C, Yau C, Banwait S et al (2007) Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer. Mol Pharmacol 71(6):1525-1534
24. Marx C, Held JM, Gibson BW et al (2010) ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination. Cancer Res 70(9):3709-3717
25. Lorch JH, Thomas TO, Schmoll HJ (2007) Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer. Cancer Res 67(2):727-734
26. Jones MD, Liu JC, Barthel TK et al (2010) A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes. Clin Cancer Res 16(20):4978-4989
27. Codony-Servat J, Tapia MA, Bosch M et al (2006) Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther 5(3):665-675